Pieris Pharmaceuticals Inc. (PIRS) Rating Reiterated by Roth Capital
Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)‘s stock had its “buy” rating reiterated by analysts at Roth Capital in a research report issued to clients and investors on Wednesday. They presently have a $6.00 price objective on the stock. Roth Capital’s price objective points to a potential upside of 257.14% from the company’s current price.
Pieris Pharmaceuticals (NASDAQ:PIRS) opened at 1.68 on Wednesday. The stock’s 50 day moving average is $1.63 and its 200 day moving average is $1.79. The company’s market cap is $72.34 million. Pieris Pharmaceuticals has a 52-week low of $1.26 and a 52-week high of $3.08.
Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Wednesday, August 10th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. Pieris Pharmaceuticals had a negative return on equity of 52.21% and a negative net margin of 346.01%. The business earned $1.07 million during the quarter. Equities research analysts forecast that Pieris Pharmaceuticals will post ($0.55) earnings per share for the current year.
A number of institutional investors have recently bought and sold shares of PIRS. Lombard Odier Asset Management USA Corp increased its position in Pieris Pharmaceuticals by 20.3% in the second quarter. Lombard Odier Asset Management USA Corp now owns 3,166,915 shares of the company’s stock valued at $5,099,000 after buying an additional 533,965 shares in the last quarter. BVF Inc. IL purchased a new position in Pieris Pharmaceuticals during the second quarter valued at approximately $389,000. Sabby Management LLC increased its position in Pieris Pharmaceuticals by 823.4% in the second quarter. Sabby Management LLC now owns 1,615,992 shares of the company’s stock valued at $2,602,000 after buying an additional 1,440,992 shares in the last quarter. Frontier Wealth Management LLC purchased a new position in Pieris Pharmaceuticals during the second quarter valued at approximately $137,000. Finally, BlackRock Fund Advisors purchased a new position in Pieris Pharmaceuticals during the second quarter valued at approximately $113,000. Hedge funds and other institutional investors own 45.79% of the company’s stock.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Stock Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.